Patents by Inventor Maria Graziewicz

Maria Graziewicz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SOLUBLE THF RECEPTORS AND THEIR USE IN TREATMENT OF DISEASE
    Publication number: 20120142759
    Abstract: The present invention relates to splice switching oligonucleotides or splice switching oligomers (SSOs). The preferred SSOs according to the invention target exon 7 of TNFR1 (TNFRSF1A) or TNFR2 (TNFRSF1A) pre-mRNA, typically resulting in the production of TNFR variants which comprise a deletion in part or the entire exon 7 respectfully. SSOs targeting exon 7 are found to result in a soluble form of the TNFR, which has thereputic benefit for treatment of inflammatory diseases. The SSO's are characterized in that they are substantially incapable or incapable of recruiting RNaseH.
    Type: Application
    Filed: October 19, 2007
    Publication date: June 7, 2012
    Inventors: Peter L. Sazani, Maria Graziewicz, Ryszard Kole
  • Soluble TNF receptors and their use in treatment of disease
    Patent number: 7785834
    Abstract: The present invention relates to tumor necrosis factor (TNF) antagonists and corresponding nucleic acids derived from tumor necrosis factor receptors (TNFRs) and their use in the treatment of inflammatory diseases. These proteins are soluble secreted decoy receptors that bind to TNF and prevent TNF from signaling to cells. In particular, the proteins are mammalian TNFRs that lack exon 7 and which can bind TNF and can act as a TNF antagonist.
    Type: Grant
    Filed: May 1, 2007
    Date of Patent: August 31, 2010
    Assignees: Ercole Biotech, Inc., University of North Carolina at Chapel Hill, Santaris Pharma A/S
    Inventors: Peter L. Sazani, Maria Graziewicz, Ryszard Kole, Henrik Ørum
  • Soluble TNF receptors and their use in treatment of disease
    Publication number: 20070249538
    Abstract: The present invention relates to tumor necrosis factor (TNF) antagonists and corresponding nucleic acids derived from tumor necrosis factor receptors (TNFRs) and their use in the treatment of inflammatory diseases. These proteins are soluble secreted decoy receptors that bind to TNF and prevent TNF from signaling to cells. In particular, the proteins are mammalian TNFRs that lack exon 7 and which can bind TNF and can act as a TNF antagonist.
    Type: Application
    Filed: May 1, 2007
    Publication date: October 25, 2007
    Inventors: Peter Sazani, Maria Graziewicz, Ryszard Kole